What Fueled The Previous Growth In The Cardiac Resynchronization Therapy Market?
The cardiac resynchronization therapy market has seen considerable growth due to a variety of factors.
• The cardiac resynchronization therapy market has seen strong growth in recent years. It will increase from $6.29 billion in 2024 to $6.74 billion in 2025, at a compound annual growth rate (CAGR) of 7.2%.
This growth is driven by the aging population, an increase in heart failure cases, growing investments in R&D for CRT devices, and increased awareness of the therapy’s benefits, alongside physician training initiatives.
What Is The Expected Growth In The Cardiac Resynchronization Therapy Market Size Evolve over the Forecast Period?
The cardiac resynchronization therapy market is expected to maintain its strong growth trajectory in upcoming years.
• The cardiac resynchronization therapy market is expected to grow to $8.77 billion by 2029, with a CAGR of 6.8%.
This growth is driven by the increasing prevalence of heart failure, a growing geriatric population, rising cardiovascular diseases, CRT therapy needs, and improvements in pacemaker and defibrillator treatments. Key trends include the adoption of CRT-D devices, advanced technology integration, expanded CRT therapy, AI adoption, and machine learning use.
What Main Forces Are Fueling Expansion In The Cardiac Resynchronization Therapy Market?
The increasing prevalence of cardiovascular diseases is expected to boost the cardiac resynchronization therapy market. Factors such as aging, unhealthy lifestyles, and poor diets are contributing to a rise in cardiovascular diseases. Cardiac resynchronization therapy (CRT) improves the heart's function by coordinating its contractions with synchronized electrical impulses. The Minnesota Department of Health reported in September 2024 that a significant portion of adults in the state have high blood pressure, leading to a greater need for CRT. Therefore, the increasing prevalence of cardiovascular diseases is pushing the growth of the CRT market.
What Are The Primary Segments In The Global Cardiac Resynchronization Therapy Market?
The cardiac resynchronization therapy market covered in this report is segmented –
1) By Type: Cardiac Resynchronization Therapy (CRT)-Defibrillator, Cardiac Resynchronization Therapy (CRT)-Pacemaker
2) By Age: Below 44 Years, 45-64 Years, 65-84 Years, Above 85 Years
3) By End-Use: Hospitals, Cardiac Care Centers, Ambulatory Surgical Centers
Subsegments:
1) By Cardiac Resynchronization Therapy (CRT)-Defibrillator: Single-Chamber CRT-D, Dual-Chamber CRT-D, Triple-Chamber CRT-D, Bi-Ventricular CRT-D
2) By Cardiac Resynchronization Therapy (CRT)-Pacemaker: Single-Chamber CRT-P, Dual-Chamber CRT-P, Triple-Chamber CRT-P, Bi-Ventricular CRT-P
Pre-Book The Cardiac Resynchronization Therapy Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Cardiac Resynchronization Therapy Market?
Major companies in the cardiac resynchronization therapy market are developing implantable devices to improve heart failure treatment outcomes. These devices synchronize heart contractions to improve pumping efficiency. In February 2024, MicroPort Scientific Corporation introduced the GALI SonR CRT-D device, which automatically optimizes heart function weekly, even during activity. This device has shown to reduce heart failure hospitalization risk by 35%, improving patient safety and treatment outcomes.
Who Are the Key Players In The Cardiac Resynchronization Therapy Market?
Major companies operating in the cardiac resynchronization therapy market are:
• Abbott Laboratories
• Medtronic plc
• Boston Scientific Corporation
• Terumo Corporation
• Biotronik SE & Co. KG
• Lepu Medical Technology (Beijing) Co. Ltd.
• Integer Holdings Corporation
• Merit Medical Systems Inc.
• LivaNova PLC
• MicroPort Scientific Corporation
• Sorin Group
• Berlin Heart GmbH
• EBR Systems Inc.
• Corvia Medical Inc.
• Recor Medical
• Jarvik Heart Inc.
• Cardiac Dimensions Inc.
• Farapulse Inc.
• Osypka Medical GmbH
• Japan Medical Device Corporation
• Imricor Medical Systems Inc.
• Vascular Dynamics Inc.
• Svelte Medical Systems
• Aleva Neurotherapeutics
• BioSig Technologies Inc.
What Is The Most Dominant Region In The Cardiac Resynchronization Therapy Market?
North America was the largest region in the cardiac resynchronization therapy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac resynchronization therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
